PDCD1 and nasopharyngeal carcinoma: In several clinical trials exploring the role of PD-1/PD-L1 inhibitors in NPC, Fang W, Ma B and Hsu C showed a good objective response rate with immune checkpoint inhibitors in patients with recurrent or metastatic NPC 5-7.